Semaglutide (Ozempic / Wegovy) Targets the GLP-1 receptor only Weekly subcutaneous injection Clinical trials showed average weight loss of 15-17% of body weight FDA-approved for weight management (Wegovy) and type 2 diabetes (Ozempic) Tirzepatide (Mounjaro / Zepbound) Targets both GLP-1 and GIP receptors (dual agonist) Weekly subcutaneous injection Clinical trials showed average weight loss of 20-26% of body weight the highest of any medication FDA-approved for weight management (Zepbound) and type 2 diabetes (Mounjaro) The SURMOUNT-1 trial, published in the New England Journal of Medicine, demonstrated that tirzepatide at the highest dose (15mg) produced an average weight loss of 22.5% nearly one-quarter of body weight over 72 weeks
Its extremely promising to think of these medicines as a new and better treatment than ever for type 2 diabetes, says Holst
If you're considering compounded semaglutide with PlexusDx and exploring NAD+ as an adjunct, discussing your genetic predispositions and current biomarkers with your provider can support a more informed, personalized treatment plan
Une tude montre que la prsence de carnitine dans les muscles diminue laccumulation des lactates de 44%
Joining Calibrate can help you achieve your weight loss goals while maintaining a healthy and well-balanced lifestyle
Vitamin D during pregnancy prevents autism-related phenotypes in a mouse model of maternal immune activation
